{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:07:36Z","timestamp":1791940056113,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijrobp.2016.03.011","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T15:54:20Z","timestamp":1459007660000},"page":"1346-1354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The\u00a0RTOG Experience"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-0406","authenticated-orcid":false,"given":"Voichita","family":"Bar-Ad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang (Ed)","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Axelrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Trotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher U.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Garden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Shenouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2016.03.011_bib1","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res"},{"issue":"21 Suppl","key":"10.1016\/j.ijrobp.2016.03.011_bib2","first-page":"47S","article-title":"Enhanced apoptosis with combination C225\/radiation treatment serves as the impetus for clinical investigation in head and neck cancers","volume":"18","author":"Bonner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib3","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermoken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib7","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.ijrobp.2016.03.011_bib9","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","volume":"21","author":"Saltz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor inhibitor cetuximab: A single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1470-2045(10)70278-3","article-title":"First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study","volume":"12","author":"Gatzemeier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib14","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdm516","article-title":"First-line single-agent cetuximab in patients with advanced colorectal cancer","volume":"19","author":"Pessino","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab induced rash: Observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib19","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ejca.2010.04.016","article-title":"Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer","volume":"46","author":"Hong","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib20","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/annonc\/mdr016","article-title":"The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: A meta-analysis","volume":"22","author":"Balagula","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib21","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2005.04.029","article-title":"Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma","volume":"41","author":"Delbaldo","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib22","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1200\/JCO.2004.00.1438","article-title":"Phase I\/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer","volume":"23","author":"Robert","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdj084","article-title":"Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma","volume":"17","author":"Folprecht","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib24","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdn150","article-title":"Cetuximab in combination with weekly 5-fluorouracil\/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib\/II study of the AIO GI Group","volume":"19","author":"Arnold","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0360-3016(03)01370-1","article-title":"Radiotherapy with concomitant weekly docetaxel for stages III\/IV oropharynx carcinoma. Results of the 98-92 GORTEC phase II trial","volume":"58","author":"Callais","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib27","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1158\/1078-0432.CCR-10-3338","article-title":"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment","volume":"17","author":"Tinhofer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"Stintzing","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Lievre","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib30","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","article-title":"Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy","volume":"96","author":"Di Fiore","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00066-009-2037-1","article-title":"High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer","volume":"186","author":"Wolff","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ijrobp.2010.01.010","article-title":"High-grade acute organ toxicity as positive prognostic factor in primary radiochemotherapy for anal cancer","volume":"79","author":"Wolff","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1148\/radiol.10100705","article-title":"High-grade organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer","volume":"258","author":"Wolff","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the\u00a0MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.011_bib35","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00520-010-0999-2","article-title":"How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?","volume":"19","author":"Chan","year":"2011","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616003230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616003230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T22:22:39Z","timestamp":1536877359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301616003230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0360301616003230"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The\u00a0RTOG Experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}